Valion Bio Weighs Sale of Velocity Bioworks After Unsolicited Acquisition Interest

Bitget2026/10/26 12:12

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold. Trade now!

A welcome pack worth 6200 USDT for new users! Sign up now!

Valion Bio is evaluating a possible sale of Velocity Bioworks following unsolicited acquisition inquiries; discussions with interested parties remain preliminary.
Any transaction would prioritize retaining production rights and continued manufacturing capabilities for Entolimod, potentially extending to other pipeline assets.
A sale could provide capital for Entolimod development and other corporate priorities; no transaction has been agreed.
Velocity will continue operating and pursuing new customers during the strategic review.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Valion Bio Inc. published the original content used to generate this news brief via ACCESS Newswire (Ref. ID: 202610260800ACCESSWRNAPR_____1241450) on October 26, 2026, and is solely responsible for the information contained therein.

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.

Trade now！

Valion Bio Weighs Sale of Velocity Bioworks After Unsolicited Acquisition Interest

You may also like

Crypto prices